KalVista generated $13.7 million in revenue from the U.S. launch of EKTERLY but reported a net loss of $49.5 million, driven largely by high selling, general, and administrative expenses related to commercialization.

KalVista generated $1.4M in initial EKTERLY sales in Q1 2026 but posted a $60.1M net loss as operating expenses surged with the launch. The company ended the quarter with $191.5M in cash and expects further regulatory decisions in Europe.

KalVista ended Q4 FY2025 with no revenue and a steep net loss of $183.4 million as it ramped up pre-launch investments for EKTERLY®, following FDA approval. Operating losses widened with increased general and administrative costs.

KalVista Pharmaceuticals, Inc. experienced a significant net loss of $48.51 million in the third quarter of fiscal year 2025, with a diluted EPS of -$0.92. Operating expenses increased, driven by a substantial rise in general and administrative costs, while research and development expenses decreased. The company's financial position was bolstered by proceeds from a royalty agreement and common stock issuance.

KalVista Pharmaceuticals reported no revenue for the second fiscal quarter ended October 31, 2024. The company's research and development expenses were $16.6 million, while general and administrative expenses were $29.2 million. The company had cash, cash equivalents and marketable securities of $135.8 million, with a pro forma balance of $292.2 million.

KalVista Pharmaceuticals reported no revenue for the first fiscal quarter ended July 31, 2024. Net loss was $40.4 million, or $(0.87) per share. Cash, cash equivalents, and marketable securities were $174.3 million on July 31, 2024.

KalVista Pharmaceuticals reported no revenue for the quarter ended April 30, 2024. The company submitted the NDA for sebetralstat to the FDA and announced the KONFIDENT phase 3 trial results. They anticipate approval and launch in the US in the first half of 2025.

KalVista Pharmaceuticals reported its third fiscal quarter results with key highlights including positive topline data from the Phase 3 KONFIDENT clinical trial and the completion of an underwritten offering that yielded approximately $150.1 million in net proceeds.

KalVista Pharmaceuticals reported no revenue for the quarter ended October 31, 2023. The company's net loss was $27.7 million, or $(0.80) per share. Cash, cash equivalents and marketable securities were $103.2 million as of October 31, 2023. The KONFIDENT trial achieved the targeted number of attacks to complete the trial.

KalVista Pharmaceuticals reported its first fiscal quarter results, highlighting the achievement of target enrollment in the Phase 3 KONFIDENT trial for sebetralstat and preparations for an NDA filing in H1 2024. The company also announced the appointment of Nicole Sweeny as Chief Commercial Officer.

KalVista Pharmaceuticals reported no revenue for Q4 2023. The company's net loss was $26.3 million, or $(0.77) per share. Research and development expenses were $24.0 million, and general and administrative expenses were $7.8 million. The company's cash, cash equivalents and marketable securities were $149.4 million on April 30, 2023. Target enrollment was achieved for the sebetralstat phase 3 KONFIDENT trial and data readout is expected in Q4.

KalVista Pharmaceuticals announced its third fiscal quarter results, highlighting significant progress in its sebetralstat development program, including the KONFIDENT phase 3 trial and new funding that extends operations into 2025. The company reported a net loss of $21.3 million, but also announced $58 million in new funding.

KalVista Pharmaceuticals reported no revenue for the second fiscal quarter ended October 31, 2022. The company's net loss was $22.3 million, or $(0.90) per share. Research and development expenses were $18.1 million, and general and administrative expenses were $7.8 million. Cash, cash equivalents and marketable securities were $122.3 million as of October 31, 2022.

KalVista Pharmaceuticals reported no revenue for the first fiscal quarter ended July 31, 2022. Research and development expenses increased to $18.2 million, and general and administrative expenses rose to $8.1 million. The net loss for the quarter was $23.0 million, or $(0.94) per share. Cash, cash equivalents, and marketable securities totaled $142.1 million as of July 31, 2022.

KalVista Pharmaceuticals reported no revenue for the three months ended April 30, 2022. Research and development expenses were $19.2 million, and general and administrative expenses were $7.6 million. The net loss for the quarter was $24.1 million, or $(0.98) per share. Cash, cash equivalents, and marketable securities totaled $166.2 million as of April 30, 2022.

KalVista Pharmaceuticals reported no revenue for the third fiscal quarter ended January 31, 2022. The net loss was $22.5 million, or $(0.92) per share. Research and development expenses were $19.7 million, and general and administrative expenses were $6.9 million. Cash, cash equivalents, and marketable securities totaled $194.8 million as of January 31, 2022.

KalVista Pharmaceuticals reported no revenue for the second fiscal quarter ended October 31, 2021. Research and development expenses were $17.5 million, and general and administrative expenses were $6.1 million. The net loss was $19.7 million, or $(0.80) per share. Cash, cash equivalents, and marketable securities totaled $209.8 million as of October 31, 2021.

KalVista Pharmaceuticals reported no revenue for the three months ended July 31, 2021. Research and development expenses were $13.7 million, and general and administrative expenses were $5.9 million. The net loss was $16.1 million, or $(0.66) per share. Cash, cash equivalents, and marketable securities totaled $230.6 million as of July 31, 2021.

KalVista Pharmaceuticals reported no revenue for Q4 2021, compared to $3.8 million for the same period in the prior fiscal year. Research and development expenses were $11.9 million, compared to $9.5 million for the same period in the prior fiscal year. Net loss was $15.0 million, or $(0.65) per share, compared to a net loss of $6.6 million, or $(0.37) per share for the same period in the prior fiscal year. Cash, cash equivalents and marketable securities were $248.9 million as of April 30, 2021, compared to $67.7 million as of April 30, 2020.

KalVista Pharmaceuticals reported no revenue for the third fiscal quarter ended January 31, 2021, compared to $1.6 million for the same period in the prior fiscal year. Research and development expenses were $9.1 million, compared to $11.2 million for the same period in the prior fiscal year. Net loss was $10.1 million, or $(0.56) per share, compared to a net loss of $9.3 million, or $(0.52) per share, for the same period in the prior fiscal year. Cash, cash equivalents and marketable securities were $50.3 million as of January 31, 2021, compared to $67.7 million as of April 30, 2020.

KalVista Pharmaceuticals reported no revenue for the quarter ended October 31, 2020, compared to $3.9 million for the same period in the prior fiscal year. Net loss was $10.4 million, or $(0.58) per share, compared to a net loss of $5.9 million, or $(0.33) per share, for the same period in the prior fiscal year. Cash, cash equivalents and marketable securities were $55.9 million as of October 31, 2020, compared to $67.7 million as of April 30, 2020.

KalVista Pharmaceuticals reported no revenue for the first fiscal quarter ended July 31, 2020, compared to $3.4 million for the same period in the prior fiscal year. Research and development expenses were $11.2 million, compared to $9.7 million for the same period in the prior fiscal year. Net loss was $10.8 million, or $(0.61) per share, compared to a net loss of $7.3 million, or $(0.42) per share, for the same period in the prior fiscal year.

KalVista Pharmaceuticals announced its Q4 and full-year financial results, highlighting revenue of $3.8 million for the quarter and a net loss of $6.6 million. The company is progressing with clinical trials for KVD900 and KVD824, with operations funded into 2022.

KalVista Pharmaceuticals reported a revenue of $1.6 million and a net loss of $9.3 million for the third quarter ended January 31, 2020. The company's research and development expenses increased due to ongoing clinical trials and preclinical activities.